Serial Number
79412149
Owner
Maxion Therapeutics LimitedAttorney
Ben NatterFiling Date
Oct 7, 2024
MAXION Trademark
Serial Number: 79412149
Trademark Classes
Class 1 - Chemicals
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Class 5 - Pharmaceuticals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Class 42 - Computer & Scientific
Scientific and technological services; industrial analysis and research services
Class 44 - Medical Services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Owner Contact Info
Legal Representation
Correspondence Address
Ben Natter Haug Partners, LLP
745 Fifth Avenue
New York, NY 10151
United States
Trademark Details
Filing Date
October 7, 2024
Registration Date
Not Registered
Published for Opposition
February 17, 2026
Goods & Services
Scientific and technological services and research and design relating thereto, namely scientific research, analysis and testing in the fields of pharmaceuticals, biochemicals, polypeptides, antibodies, ion channel modulating antibodies, and G-protein-coupled receptor modulating antibodies and antibodies derived from mini-protein toxins; drug discovery and drug development services; conducting or providing research and development services for others in the field of antibodies; medical and scientific laboratory services relating to the production of antibodies, ion channel modulating and G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins; antibody engineering; scientific research services relating to the discovery, preclinical and clinical development of therapeutic products; information, advisory and consultancy services in relation to all of the aforesaid
Medical services; medical diagnostic testing, analysis and diagnostic services for the treatment of patients in the field of antibodies; medical services for the treatment of diseases through the use of antibodies, ion channel modulating antibodies, and G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins, or pharmaceuticals, drugs and pharmaceutical preparations derived from the aforesaid; information, advisory and consultancy services in relation to all of the aforesaid
Biochemicals, namely, polypeptides and engineered antibodies for scientific, laboratory or research purposes; polypeptides and engineered antibodies for use in the manufacture of pharmaceuticals and drugs; ion channel modulating and G-protein-coupled receptor modulating engineered antibodies for scientific, laboratory or research purposes; ion channel modulating and G-protein-coupled receptor modulating engineered antibodies for use in the manufacture of pharmaceuticals and drugs; engineered antibodies derived from mini-protein toxins for scientific, laboratory or research purposes; engineered antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs
Pharmaceuticals and pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel and G-protein-coupled receptor activity, in particular, preparations for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; drugs, namely, pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel and G-protein-coupled receptor activity, in particular, those for use in the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; antibodies for medical use; pharmaceuticals and drugs in the nature of pharmaceutical preparations incorporating antibodies, ion channel modulating antibodies, and G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins for the treatment of diseases and conditions associated with dysregulation of ion channel and G-protein-coupled receptor activity, in particular, those for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; human vaccine preparations